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THE PROMISE OF INDIVIDUALIZED MEDICINE
ABSTRACT
Pharmacogenomic technologies promise to usher in an era of individualized medicine, but also pose chal-
lenges to a regulatory regime without experience dealing with the sorts of data produced by these tech-
niques. Pharmacogenomics as a ﬁeld encompasses both “pharmacogenetic” techniques, which tend to focus
on polymorphisms in cytochromes and other proteins involved in drug metabolism, and “pharmacogenomic”
techniques such as microarray technologies, which examine disease and drug interactions on the level of
the entire genome. In 2003, the FDA produced a guidance recommending procedures for the submission of
pharmacogenomic data at the IND or NDA stage. While pharmacogenomic information used in “decision
making” during trials is required, most pharmacogenomic data of an exploratory nature may be submitted
voluntarily under a separate protocol. Though these procedures seem a reasonable means by which the FDA
can open a dialogue with pharmaceutical manufacturers regarding the use of pharmacogenomic data, more
action is necessary to develop the infrastructure necessary to develop the technology such that in may be
incorporated in regulatory decisions with conﬁdence.
I. INTRODUCTION
2Ultimately, the medical profession treats patients, not conditions. Factors such as a patient’s pattern of
diet and exercise, occupational hazards, stresses, and personal medical histories will aﬀect the course of
treatment signiﬁcantly. Diagnosis of a disease state is only one step among many necessary to develop an
eﬀective treatment regime. Ideally, many factors that might vary from patient to patient would be taken
into account by a treating physician. Though fulﬁllment of the promise of “individualized medicine” is still
some years away, much of the technology that could tailor treatment regimes to individual patients’ genetic
compositions – referred to as “pharmacogenomics” – is here. Given its integral role in inﬂuencing drug
development strategies, the Food and Drug Administration (FDA) must begin to structure its requirements
for submission of clinical data to accommodate pharmacogenomics, and must do so in the manner that best
complements the development of the underlying technology.
When the FDA conﬁrms the safety and eﬃcacy of a medication, it approves the ﬁtness of the drug for the
treatment of a speciﬁc indication. In fact, many drugs are approved with as little as 30% eﬃcacy among
the general patient population.1 The degree of speciﬁcity of this indication will vary, however. In a clinical
setting, a medication is indicated for a condition if the detectable symptoms place the condition among
the constellation of disorders that the medication has treated eﬀectively in trials. If there is not some
reliable measurable or observable characteristic that will diﬀerentiate the condition of one patient from that
of another in a way that would predict a diﬀerent response to the drug, the medication is approved for both
patients. Some drugs will be ruled out for a given patient because they interact adversely with other drugs
or cannot be used given certain metabolic disorders. For the most part, however, the variance in patient
response is neither understood nor accounted for during the approval process.
Of course, there are very good reasons why the FDA cannot guarantee safety and eﬃcacy for every patient
taking a given medication and must often rely on trials that are not stratiﬁed on the basis of expected
1See Allen D. Roses, Pharmacogenetics and Drug Development: The Path to Safer and More Eﬀective Drugs, 5 Nature
Reviews: Genetics 645, 648 (2004)
3response. Putting aside the more familiar limits to assurance of safety and eﬃcacy – degrees of patient
compliance or diﬀerences in diet, for example, or the ethical paradox involving informed consent for trials
involving children – some divergent patient responses are simply beyond the capacity of current medical
technology to predict. Some variations could be due to diﬀerences in the underlying condition that are
not readily diagnosed in a clinical setting, such as the precise identity of a pathogen or type of tumor.
Other variations in patient response might be due to genetic diﬀerences that could account for variations
in the bioavailability or metabolism of diﬀerent medications, in the immune responses of patients, or in the
etiologies of tumors.
Pharmacogenomics and pharmacogenetics promise to improve patient care by providing insight into the
genetic components underlying the distribution of patient responses to disease and to treatment. Although
these technologies are progressing rapidly, they are still in their nascent stages of development, and their
utility in a clinical setting has not been established. As they have begun to mature and certain genotypes have
been validated as predictive of clinical outcomes, questions have emerged regarding the FDA’s requirements
for submission of pharmacogenomic data along with INDs, NDAs, or BLAs. The FDA sought to address
these issues through a workshop involving industry representatives and FDA oﬃcials,2 and these meetings
eventually resulted in the publication of a draft guidance3 outlining FDA policy.
Because Congress has charged the FDA with safeguarding the supply of pharmaceuticals and biologics in
the marketplace, FDA policy inevitably will play a major role in shepherding these promising technologies
to maturity and into widespread clinical use. As FDA formulates policy, administrators must keep in mind
2Lawrence J. Lesko, et al., Pharmacogenomics and Pharmacogenomics in Drug Development and Regulatory Decision
Making: Report of the First FDA-PWG-PhRMA-DruSafe Workshop, 43 J. Clinical Pharmacology 342 (2003)
3U.S. Dep’t of Health & Human Services, Food & Drug Admin., Center for Drug Evaluation & Research (CDER),
Center for Biologics Evaluation & Research (CBER), Center for Devices & Radiological Health (CDRH), Guid-
ance for Industry: Pharmacogenomic Data Submissions (November, 2003) (hereinafter “Guidance”)
4a set of challenges that pharmacogenomics presents – challenges that are ethical, economic, and scientiﬁc in
nature. This paper is designed to survey some of the emerging technologies and discuss some of the concerns
the FDA has considered regarding their use in drug development.
II. PHARMACOGENETICS AND PHARMACOGENOMICS
While the terms are often used interchangeably, it may be useful to draw a functional distinction between
pharmacogenetics and pharmacogenomics. The distinction is somewhat historical, as the term “pharmaco-
genetics” was ﬁrst used to describe the study of genetic variation in genes such as the CYP450 family (dis-
cussed below,) involved in primary drug metabolism.4 The term “pharmacogenomics” refers to a more recent
approach to the study of genetic and pharmacologic interaction on the level of the whole genome, wherein
multiple genes or gene products are monitored in parallel and their interactions observed.. Because variations
in proteins with a variety of functions, such as transporters and receptors, will aﬀect metabolism, “phar-
macogenomics” may be used both to distinguish studies broader than those focused on well-characterized
metabolic enzymes, and to reﬂect the highly cooperative, complex processes underlying the eﬃcacy, toxicity
and metabolism of drugs.5
A. Pharmacogenetics
It has long been known that propensities toward certain illnesses have a genetic component. Even forty
years ago, researchers were able to attribute diﬀerences in the metabolism of certain chemicals to variation
in individual genes. In the 1960s, researchers recognized that inherited variation in the genes encoding the
4B.P. Sweeney, Microarrays: New Pharmacogenomic Tools for the Twenty-First Century, 21 Euro. J. of Anaesthesiology
505 (2004)
5Id.
5enzymes butyryl-cholinesterase and N-acetyltransferase correlated with diﬀerences in the plasma or urine
concentrations of diﬀerent drugs.6 In the late 1980s, studies found a correlation between diﬀerences in
metabolism of certain drugs and polymorphisms7 in a set of liver enzymes called cytochromes. Researchers
found that several diﬀerent variations in the sequence of the gene encoding cytochrome P-450 2D6 (CYP2D6),
a protein involved in the metabolism of many drugs, correlated with rates of drug metabolism both more
rapid and slower than typically seen in the population.8
Cytochrome P450 molecules are membrane enzymes containing iron that oxidize a wide variety of substrates
– a surprisingly chemically diverse set of therapeutic molecules are metabolized by the same enzymes.7,8
The addition of an oxygen atom to a substrate will tend to improve the solubility of the molecule, generally
an early step in the metabolism of lipid-based molecules.9 In the late 1970s, researchers found a correla-
tion between polymorphisms in the gene encoding cytochrome CYP2D6 and the metabolism of the drug
debrisoquine, used to treat hypertension.10 The CYP2D6 gene was later isolated, and it was found that
a number of CYP2D6 polymorphisms persist in the general population. Comparing these polymorphisms
with metabolic rate revealed a striking correlation. It was found that individuals with multiple copies of
the gene metabolized many drugs more rapidly than those with a single copy. Individuals with mutations
resulting in splicing errors or changes to amino acid sequence often had higher blood plasma concentrations
of the drug, indicating slower metabolism. To date, 75 diﬀerent alleles have been found, many of which
are single nucleotide variations.11 Despite this diversity, individuals are divided into four classes based on
6Richard Weinshilboum, Inheritance and Drug Response, 348 New England J. of Med. 529 (2003).
7A genetic polymorphism is deﬁned to occur when two or more diﬀerent single gene variants persist in more than 2% of
a population. See Skada, R,... , Meyer, U, Two Mutant Alleles of the Human Cytochrome P-450db1 (P450C2D1) Gene
Associated with Deﬁcient Metabolism of Debrisoquine And Other Drugs. 85 Proc. Nat’l. Acad. Sci. 5240 (1988).
8See Weinshilboum, supra note 6, at 530.
9See http://www.its.caltech.edu/∼atobias/RUP-p450.html, last visited 3/16/05 (for a very humorous and only mildly
objectionable website posted by an apparently very enthusiastic researcher, that, perhaps despite itself, gives a nice introduction
to CYP450 basics for the layperson.)
10See Weinshilboum, supra note 6 at 530
11See id. at 532
6their CYP2D6 activity: patients with “ultrarapid metabolism” have multiple copies of the CYP2D6 gene,
patients with “extensive metabolism” have a single working copy, and patients with slower enzymatic rates
are characterized as having either “intermediate” or “poor metabolism.”12 While nearly 75% of individuals
exhibit “extensive metabolism,” the other classes are populated signiﬁcantly. The frequency of alleles diﬀers
if patients are grouped by ethnicity. For example, 5 to 10% of whites and 1% of persons of Chinese or
Japanese descent exhibit poor metabolism.13
Of the cytochromes, CYP2C9, CYP2C19, and CYP2D6 account for 40% of total cytochrome activity and
show the most pronounced correlation between polymorphism and total metabolic rate.14 As a ﬁnite set of
enzymes involved in the metabolism of numerous drugs, they represent promising candidates for genotyping
in a clinical setting. If successful, clinical genotyping could become a routine procedure of use in the dosing
of drugs, improving both safety and eﬃcacy.
A number of diagnostic test kits have already been developed for use in a clinical laboratory setting. The
pharmaceutical company Roche received FDA approval for the “AmpliChip CYP450” test system in January
of 2005.15 The AmpliChip uses technology developed by the Aﬀymetrix corporation in the context of
genomic research and, according to Roche, will test for 29 diﬀerent polymorphisms of CYP2D6 (including
gene duplication and deletion) and two major polymorphisms in CYP2C19.16 Essentially, the “AmpliChip”
device contains over 15,000 25 nucleotide strands (“oligonucleotides”) arrayed regularly on a glass chip the
12See Yosef Caraco, Genes and the Response to Drugs, 351 New England J. of Med. 2867 (2004)
13See id. at 2868
14See id. at 2868.
15See Roche, Inc., Roche’s AmpliChip CYP450 Test Receives FDA Clearance. Press Release (January, 2005)
16See id.
7size of a dime. By amplifying and ﬂuorescently labeling certain segments of DNA gained from a subject’s
blood sample, then allowing the products to form speciﬁc hydrogen bonds with the oligonucleotides ﬁxed
to the chip (the same speciﬁc interactions that hold together the two complementary strands of a DNA
molecule,) a technician can determine a patient’s genotype.
The AmpliChip is a diagnostic test that could be used to determine the dosing of a host of drugs the
metabolism of which correlates with the function of CYP2D6 and CYP2C19. Until such testing is so cost
eﬀective as to be routine, however, it is likely that drugs developed and co-marketed with speciﬁc genetic
tests will be more common. The ﬁrst treatment co-marketed with a diagnostic test was the breast cancer
drug trastuzumab, marketed by Genentech as Herceptin.17
Herceptin is a monoclonal antibody, rather than a small molecule drug, and hence binds to a speciﬁc
antigen, the ERBB2 receptor.18 The ERBB2 protein, which binds the receptor, is overexpressed in some
breast tumors.19 Like most eﬀective small molecule drugs, antibodies bind only to speciﬁc epitopes (a part
of a protein or other chemical signature that the antibody can recognize,) and an antibody to the ERBB2
receptor will be useful as a therapeutic agent only where blocking the ERBB2 protein from binding to its
receptor will have some eﬀect on the growth or progression of a tumor. Examining data following Phase III
trials revealed that Herceptin was more eﬀective in tumors where ERBB2 was overexpressed. Patients must
take a diagnostic test to determine the extent of ERBB2 expression before they are prescribed Herceptin.
B. Pharmacogenomics
17See Roses, supra note 1 at 648.
18See id.
19See id.
8Pharmacogenomic technologies are primarily useful in two areas: gene expression analysis and examination
of single nucleotide polymorphisms (SNPs) linked to phenotypes demonstrative of eﬃcacy or safety. Other
technologies, such as “metabolomics” or “proteomics” are similar in approach but utilize diﬀerent analytes
– metabolites and proteins, respectively. All of these technologies involve parallel monitoring of all analytes
of a given type in a cell or tissue in response to diﬀerent conditions, such as disease states.
Microarrays for Gene Expression
Microarray technology can be used to monitor the “transcriptome,” or the complete set of gene transcripts
produced by a cell. Messenger RNA (mRNA) is an intermediate between genes and proteins. Ribosomes,
complexes of RNA and protein, synthesize proteins from mRNA “transcripts” of DNA sequences. The mRNA
sequences are essentially duplicates of the nucleotide sequences of genes. A cell does not need its entire
complement of proteins produced simultaneously – in fact, this would be highly detrimental. Moreover, in
complex organisms, all cells, even given highly divergent functions, contain complete copies of an organism’s
genome. In order to respond to diﬀerent conditions and develop diﬀerent tissues to mediate diverse functions,
regulation of gene expression at the cellular level is critical. Diﬀerent genes will be expressed in diﬀerent
cell types and under diﬀerent conditions. Gene regulation occurs at many stages, but the most energetically
eﬃcient regulation of gene expression will modulate the concentration of mRNA. Cells accomplish this
modulation through control of the rates of mRNA synthesis from genes (transcription) as well as mRNA
degradation and modiﬁcation processes.
9For example, suppose gene A encodes an enzyme involved in breaking down a given toxin. Under normal
conditions, with scarce raw materials and energy, the cell will focus its productive capacities most eﬃciently
elsewhere, producing structural proteins or proteins that mediate basic metabolic functions. When the cell
is exposed to increased quantities of the toxin, however, the cell will need increased quantities of the protein.
The cell might then produce more of the mRNA transcript encoding the protein, or alter the mRNA or
proteins that bind to it in such a way that it is degraded at a lower rate or “translated” into protein more
quickly. Whether the degradation of the mRNA slows or its synthesis increases, the net result upon exposure
to the toxin will be an increased concentration of the mRNA transcript of gene A.
Microarrays allow a “snapshot” of all of the mRNAs in a given population of cells given a change in condi-
tion.20 A microarray is typically a glass slide, about 1 cm2 upon which whole genes or fragments of genes
representing the entire known complement of genes of a given organism, or a set of genes known to be ex-
pressed in a given tissue, has been arrayed in “spots” in a regular fashion. The mRNA from a given sample
– typically a time point21 – will be ﬂuorescently labeled. These ﬂuorescent copies will then be put in contact
with the microarray surface and allowed to bind (“hybridize”) through speciﬁc base-pair interactions to the
genes or gene fragments on the array. Depending on the array system, the relative concentrations of a given
gene can be determined by level of ﬂuorescence on two diﬀerent arrays, or by relative amounts of samples in
a given spot labeled to ﬂuoresce with diﬀerent colors on the same array.22
The ability to follow all genes simultaneously is crucial. To return to the example of “gene A,” inevitably,
the A enzyme will not act alone in response to the introduction of the toxin, but as part of a complex of
20See, e.g., Mark Schena, et al., Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microar-
ray, 270 Science 467 (1995)
21a sample taken at a ﬁxed interval, as in any Phase I clinical trial
22See Schena, supra note 20; Deval A. Lashkari, et al., Yeast Microarrays for Genome Wide Parallel Genetic and Gene
Expression Analysis, 94 Proc. Nat’l Acad. Sci. 13057 (1997)
10proteins or simply as one component of a metabolic pathway. Changes in the concentrations of the mRNA
encoding at least some of those proteins would be predicted as well.23 Hence, microarrays are a useful tool
for scientists seeking to understand how gene products act in concert, or how a cell deals with diﬀerent
stresses or conditions on the level of the entire genome. Furthermore, if the function of a gene product is
unknown, its patterns of expression across a range of conditions might provide some clues.
Beyond these basic research applications, microarrays are useful in drug development and diagnosis through
the establishment of biomarkers and identiﬁcation of target genes. Essentially, the patterns of expression
elucidated on an array in response to a certain condition may provide valuable information even where
important components of a pathway are not regulated at the transcriptional level, or where the function of
certain genes is unknown. For example, patterns of expression may be seen to repeat whenever compounds
are toxic or carcinogenic in animals, or where a favorable treatment outcome, such as remission of a tumor or
reduction of a toxic metabolite develops.24 Where such patterns could be used to reliably predict treatment
outcomes, the patterns could act as “biomarkers,” potentially rendering drug development more eﬃcient by
more accurately predicting long-term outcomes in shorter intervals.
In 2001, an NIH working group deﬁned a “biomarker” as “a characteristic that can be objectively mea-
sured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological
responses to a therapeutic intervention,” and put biomarkers in three classes: “those that track disease
progression over time and correlate with known clinical measures; those that detect the eﬀect of a drug; and
those that serve as surrogate endpoints.”25
23There are, of course, ways a cell could deal with a change in conditions that might not be detectable as a change in mRNA
concentration. For example, numerous protein-protein interactions are mediated by the phosphorylation of proteins or other
post-translational modiﬁcations.
24See Julie Wakeﬁeld, FDA Eyes Pharmacogenomic Data, 112 Envtl Health Perspectives A217 (2004).
25Jennifer Van Brundt, Biomarkers, The Pendulum Finally Swings, Signals Magazine (October, 2004), at
11Biomarkers that act as surrogate endpoints may be especially useful in clinical trials and treatment. For
some conditions, it will not be feasible to direct a clinical trial that monitors patients for the duration
necessary to observe the desired treatment outcome. If a biomarker can be established early in the course
of treatment, the ultimate success of a drug can be established faster, and at much lower cost. The same
is true for biomarkers indicative of toxicity. For example, carcinogenicity could be detected early in animal
trials, enhancing safety.
SNPs
Researchers can also use parallel systems to type patients for single nucleotide polymorphisms, or “SNPs.”26
SNPs are useful both for mapping genes, and as a readily detectable indicator of genotype, given close linkage
to a gene or trait of interest. Mapping is a statistical technique based on the premise that adjacent areas of
a chromosome will cosegregate more frequently than distal areas during meiosis, when recombination occurs
between the copies of chromosomes inherited from each parent during the formation of germ line cells. If,
to a ﬁrst approximation, the frequency of chromosomal crossover at any given point along a chromosome is
equal, the closer together two sequences are, the less frequently a crossover will occur between them, and
the more frequently they will be observed on the same chromosome.
Linkage disequilibrium (LD) studies are useful for ﬁnding the genetic bases for complex traits – phenotypes
governed by multiple genes. Essentially, if certain SNPs are seen to comigrate more frequently than would
be expected from random mating in the population, it is likely that both loci are somehow involved with
http://www.signalsmag.com/signalsmag.nsf/0/4D214C0B5216A2BC88256F3300693C21
26See Anne-Christine Syvanen, Accessing genetic variation: genotyping single nucleotide polymorphisms, 2 Nature Reviews:
Genetics 930 (2001) (“Comparison of genomic DNA sequences in diﬀerent individuals reveals some positions at which two, or
in some cases, more than two, bases can occur. These single nucleotide polymorphisms (SNPs)... are estimated to occur at one
out of every 1,000 bases in the human genome.”
12the maintenance of the phenotype of interest, such as positive response to a drug.27
A number of methods exist allowing genotyping of SNPs, including those utilizing microarrays.28 The
Aﬀymetrix “GeneChip” system, a microarray system also used in gene expression studies, allows suﬃciently
high density arraying of oligonucleotides (106 oligonucleotides per cm2) to allow sequences containing a num-
ber of diﬀerent possible SNPs (allele speciﬁc oligonucleotides, or “ASOs”), along with ﬂanking sequences.29
When a sample, generated by PCR ampliﬁcation of a given region of a subject’s genomic DNA, is added to
the array, more stable hybridization will generally occur where the printed oligonucleotides more closely com-
plement the oligonucleotides in the sample.30 Other techniques utilize various enzymes’ abilities to recognize
and diﬀerentiate between double stranded DNA structures and double-stranded structures interrupted by a
mismatched pair of nucleotides. Methods using PCR take advantage of two activities of DNA polymerases,
both an exonuclease activity that degrades double stranded sequences, and the polymerase activity itself,
which will be inactive if blocked by a mismatch.31
Among the greatest beneﬁts of pharmacogenomics to the pharmaceutical industry could be the use of genetic
biomarkers such as SNPs to enrich clinical trials for responsive patients.32 According to Glaxo researcher
Allen Roses, “[i]n practice, most candidate drugs that reach human testing fail in Phase IIA.”33 Pharma-
ceutical companies tend to abandon drugs in development if there is eﬃcacy only in a small subgroup.34
If pharmacogenetic tests could allow for diﬀerentiation between a small set of responders and a larger set
27See Roses, supra note 1 at 648.
28See Syvanen, supra note 26 at 933.
29See id.
30See id.
31See id.
32See Roses, supra note 1 at 647.
33Id. (“Phase IIA is the ﬁrst time that a molecule is tested for its desired clinical eﬀect in humans.”)
34See id. at 648.
13of non-responders, development could move forward, with trials enriched for individuals positive for that
biomarker.35
III. FDA GUIDANCE
In human trials, the correlation of expression biomarkers, for both safety and eﬃcacy, and genetic biomarkers
could work to select a speciﬁc group of patients for whom a given treatment is safe and eﬀective. Such an
application of pharmacogenomic technology would allow treatment very close to “individualized medicine.”
Much like Herceptin, a medication could be marketed with a genetic test that will be used to determine
whether the medication will be safe or eﬀective for a given patient at a given dose.
Before entering the marketplace, however, pharmacogenomic techniques must be proven eﬀective in predict-
ing outcomes, and it is the FDA with whom the decision regarding the reliability of clinical trials has been
entrusted. In order to facilitate this sort proof of principle on a large scale – and to a degree of proof that
will allow the public conﬁdence in the eﬀorts of the biotech and pharmaceutical industries – the FDA has
released its ﬁrst guidance to solicit pharmacogenomic data submissions from pharmaceutical companies.
In November of 2003, the FDA published a draft guidance designed to introduce both the agency and
pharmaceutical manufacturers to the use of pharmacogenomic data in submissions to be evaluated by the
FDA.36 The guidance subsumed the term “pharmacogenetics” under the broader term “pharmacogenomics”
to deﬁne the ﬁeld, but distinguished “pharmacogenetic tests,” deﬁned as assays studying genetic variation
“related to drug absorption and disposition (pharmacokinetics) or drug action (pharmacodynamics)” from
35See id.
36See Guidance, supra note 3.
14“pharmacogenomic tests,” which assay “variations in whole-genome or candidate gene single-nucleotide poly-
morphism (SNP) maps, haplotype markers, and alterations in gene expression or inactivation that may be
correlated with pharmacological function and therapeutic response.”37 Signiﬁcantly, the guidance expressly
disclaims any relevance to proteomic techniques, in which biotech companies are making large investments,
and which the FDA will at some point need to explore.38
The guidance does not require submission of pharmacogenomic data with all clinical trials. Submission is
required only where pharmacogenomic data is obtained and relied upon for decision making during the IND
or NDA phase. Under administrative law, none of the procedures are discussed in language that would
suggest they are mandatory. The protocols discussed were not regulations promulgated through notice and
comment rulemaking procedures. However, in practice, pharmaceutical companies will attempt to comply.
Generally, however, the guidance does not make pharmacogenomic research a standard component of submis-
sions because the FDA simply lacks the expertise with pharmacogenomic data to make regulatory decisions,
and because “most experimental results may not be well enough established to be suitable for regulatory
decision making.”39 To assist in the standardization of procedures and to familiarize the FDA with phar-
macogenomic data, the guidance introduces a format by which such exploratory data can be volunteered by
drug companies.
Fundamentally, the guidance creates procedural distinctions based on the degree to which a given test
has been proven reliable and empirically corroborated. The guidance deﬁnes a “valid biomarker” as a
pharmacogenomic test which is “measured in an analytical test system with well-established performance
characteristics” and for which “there is an established scientiﬁc framework or body of evidence that elucidates
37Id. at 15.
38See Van Brundt, supra note 25.
39Guidance, supra note 3, at 2.
15the physiologic, pharmacologic, toxicologic, or clinical signiﬁcance of the test results.”40 Essentially, any
data presented to the FDA that was derived using a pharmacogenomic technique must be generated using a
technique that is reliable and must have considerable empirical support. At this stage, then, it does not seem
that a mere correlation between a pattern of gene expression and treatment outcome would be considered
“valid” until some “elucidat[ion]” of the “scientiﬁc framework” within which the data can be understood.
Some study of mechanism would appear to be necessary, especially for a result to have an empirical grounding
similar to data regarding the cytochromes. The guidance oﬀers the example of a genetic test to determine
a patient’s CYP450 2D6 allele as a valid biomarker.41
The guidance further diﬀerentiates between “known” and “probable” valid biomarkers.42 “Known” valid
biomarkers “have been accepted in the broad scientiﬁc community.” Data suﬃcient to validate a biomarker,
but that have not been vetted by the scientiﬁc community, may establish a “probable valid biomarker.”
Other pharmacogenomic data that may be useful in drug development need not be submitted.
Pharmacogenomic data is to be submitted as part of an IND under § 312.23 under three conditions: (1)
the test results are “used for decision making”; (2) the test results are used to support scientiﬁc arguments;
or (3) the results are a known, valid biomarker. At the NDA stage, pharmacogenomic data intended to be
included in the label are to be submitted with the NDA. Data on known or probable valid biomarkers are
to be submitted with the NDA as “abbreviated reports.”43
The guidance recognizes that most pharmacogenomic data will not meet the requirements for known or
40Id. at 4.
41Id.
42Id.
43Id. at 9.
16probable valid biomarkers.44 Because the FDA anticipates that pharmacogenomic data will be a standard
component of future submissions, however, the guidance establishes a structure submission of exploratory
pharmacogenomic data as “voluntary genomic data submissions” (VGDSs).45 VGDSs will be reviewed
by an “Interdisciplinary Pharmacogenomic Review Group” (IPRG).46 The FDA contemplates that such
submissions might include gene expression data obtained using microarrays or SNP proﬁling of participants
in clinical trials.47 The FDA is adamant that data submitted under the voluntary protocols will not aﬀect
the approval process. Only if further information indicates that the data in the VGDS must be submitted
with an NDA or BLA will the data be required to be resubmitted and used in the approval process.48
IV. ANALYSIS – THE GUIDANCE AND THE ROLE OF THE FDA
The issuance of the 2003 guidance was preceded by a meeting of a working group involving representatives
from the FDA, the Pharmacogenetics Working Group (PWG), the Pharmaceutical Manufacturers of America
(PhRMA), and PhRMA’s Preclinical Safety Committee (DruSafe) in May, 2002.49 The workshop concluded
that although pharmacogenomic technologies have potential to improve the safety and eﬃcacy of
drugs when used at all stages of clinical trials, because the technologies are new and largely unproven, regula-
tory bodies and developers must establish certain standards and reference populations for pharmacogenomic
analysis. For example, the workshop report notes that both sample size requirements and the ethnic compo-
sition of groups involved in pharmacogenomic studies must be established.50 Given multiple methods of SNP
44See id. at 6.
45Id.
46Id.
47See id. at 10.
48See id. at 11.
49See Lesko, supra note 2.
50See id. at 344.
17detection, pharmaceutical manufacturers would have a strong interest in having FDA develop a standard for
validation before investing in the infrastructure necessary to generate data using a given technique, as well.
The workshop report notes that “[w]ith regard to the use of SNP and haplotype assay technology and the
validation of these methods, there was consensus for a need for standardized reference materials, standards
for assay validation, and speciﬁc regulatory guidance for validation criteria of the methods.”51
For microarray data, there was concern that methods were not yet suﬃciently reproducible to be useful
in a clinical setting. Generally, it was recognized that microarray data is highly cumulative, and that a
large database would be beneﬁcial. Many participants suggested that the FDA require any microarray
data from experiments with compounds for which an IND has been ﬁled.52 Because data could become
more informative after submission but before approval, all participants wanted “highly transparent” FDA
procedures.53
With regard to the use of pharmacogenomic tests in clinical trials, the workshop found promise in all
stages. The report notes that the administration of a range of doses during Phase I is especially useful in
conjunction with pharmacogenomic and pharmacogenetic tests, oﬀering an opportunity to correlate gene
expression with dose and response, and to examine adverse events more fully.54 There was some debate
among workshop participants regarding whether adverse events correlated with genotype would warrant
stratiﬁcation or even require inclusion or exclusion at Phase II, with some participants suggesting that data
that was exploratory at Phase I could be conﬁrmed during Phase II given the broader samples utilized.55
Well-established biomarkers, such as the CYP2C and D family, were felt to be suﬃciently validated to allow
51Id.
52See id. at 345.
53Id.
54See id. at 349.
55See id.
18them to act as
inclusion/exclusion or stratiﬁcation criteria.56 Generally, “there [was] more willingness to stratify based on
pharmacogenomics and pharmacogenetics for safety than for eﬃcacy.”57 For well-studied genes such as the
cytochromes, an analogy could be drawn “to the study of patients with reduced renal function,” and hence,
developers would have some experience administering trial representation in this manner.58
For broader, Phase III trials, the report notes some question regarding the breadth of the test pool given
some indication from earlier phases that the safety or eﬃcacy of a drug will vary with genotype.59 Though a
correlation might be seen between genotype and therapeutic outcome in early stages, testing on individuals
negative for the biomarker indicative of favorable outcome might still be beneﬁcial. This beneﬁt would derive
not only from the opportunity to examine further data to validate the biomarker at issue. Additionally, one
might expect that, even given biomarkers indicative of safety or eﬃcacy, the medications will be used by
patients who are negative for the relevant biomarker.
Given this background, it is worth asking whether the FDA guidance of 2003 promulgated the best possible
system for balancing economic incentives, consumer welfare, and a need to shepherd pharmacogenomic
technology to maturity. Though the FDA recognizes “concern” among pharmaceutical manufacturers that it
will have some diﬃculty incorporating pharmacogenomic data into the approval process, the guidance argues
that the agency “has considerable experience” incorporating data that “predict increased risk of adverse
events, or point to enhanced probability of response,” such as information on “drug metabolizing phenotypes”
56See id.
57Id.
58Id. at 350.
59See id. at 352.
19or “conditions or co-factors that may increase an individual’s susceptibility to an adverse event.”60 Among
this latter category, the guidance lists “co-morbid conditions, metabolic susceptibilities such as renal or
hepatic failure, or interacting drugs.”61 Generally, the FDA does not anticipate that pharmacogenomic data
will “give deﬁnitive answers about safety and eﬀectiveness in subpopulations.”62 Rather, pharmacogenomic
data will be one factor among many inﬂuencing how patients respond to treatment, and hence “genetic
markers can ordinarily be handled like other predictive markers in the clinical area.”63 In oncology, however,
the agency predicts that the data may have more immediate and deﬁnitive impact.64
With respect to biomarkers indicative of toxicity, the gradual process anticipated by the FDA is probably an
accurate prediction of how pharmacogenomic data will be introduced to the drug development process. A
study conducted by the Wellcome Trust examined the clinical use of clozapine, an antipsychotic drug used
among patients for whom other drugs are either ineﬀective or cannot be tolerated.65 Clozapine can cause
agranulocytosis, a potentially fatal blood disorder.66 Clinicians were skeptical that a test could predict the
occurrence of the disorder to an extent that would obviate expensive blood monitoring, and given the use
of clozapine in patients who had not responded to other drugs, clinicians were reluctant to rule out patients
based on genetic data.67 There was also concern that treatment endpoints for schizophrenia were diﬃcult
to establish,
60Guidance, supra note 3 at 13.
61Id.
62Id. at 14.
63Id.
64See id.
65Andrew Webster, et al., Integrating Pharmacogenetics into Society: In Search of a Model, 5 Nature Reviews: Genetics
663 (2004).
66See id. at 665.
67See id.
20making biomarkers diﬃcult to establish, as well.68
Given the diﬃculties accompanying the introduction of pharmacogenomic information at the clinical level,
the FDA’s cautious approach is understandable. Unless a diagnostic test is developed rigorously alongside a
medication, it is unlikely that genetic information will provide more than a loose correlation between genotype
and treatment outcome – a correlation that may not justify denying a patient treatment, depending on the
clinical context.
The FDA’s refusal to require submission of or base approval on the sort of pharmacogenomic research
considered appropriate for VGDS submission is also likely an appropriate protocol to foster development
of pharmacogenomics without overly hindering research by requiring use of an unproven technology. For
pharmacogenomic techniques such as microarrays and SNP mapping to become commonplace, more data are
needed. The more conditions under which gene expression is studied, the more robust and reliable certain
biomarkers will be. For example, the same set of genes may be seen to exhibit changes in expression in
response to a certain class of medicines, but only given one of two genotypes for cytochromes or transport
proteins. While the FDA can play a role in encouraging pharmaceutical companies to use pharmacogenomic
testing or pool results, ultimately, the sort of basic research infrastructures necessary to improve the reliability
of pharmacogenomic data will likely need to come from other sources.
68See id.
21For example, as new SNPs have been discovered in the human genome, they have been placed in the public
domain by a consortium of pharmaceutical companies and research institutions with the understanding
that they will ultimately be of greater beneﬁt as a publicly available resource.69 Similar eﬀorts to create
a database of microarray data would also be highly beneﬁcial. For these data to be useful, however, some
greater standardization of protocol is likely needed, so that meaningful comparison of data can be undertaken.
The FDA could be instrumental in developing such standards through analysis of its analysis of VGDS data.
In developing a protocol for submission of pharmacogenomic and other data, FDA must accommodate both
the rapid development of array technology and the evolution of similar technologies such as proteomics and
metabolomics. Both of these issues present the same basic challenge – ensuring that FDA procedures are
able to accommodate technological growth without requiring a disruptive paradigm shift in clinical testing
protocols or submission format.
Ideally, data in each area – gene expression, proteomics or metabolomics – would be suﬃciently standardized
to allow comparisons across the widest possible range of conditions. Additionally, any standard must be
independent of any individual platform, to avoid unduly hindering advances in the underlying technology.
(1) Technique validation
The FDA could move to sanction platforms through a formal review process in much the same way that
diagnostic tests are validated. Because platform approval would consist of a “proof of principle” pilot
69See Barbara Ann Binzak, How Pharmacogenomics Will Impact the Federal Regulation of Clinical Trials and the Drug
Approval Process, 58 Food & Drug L. J. 103 (2003)
22experiment designed to replicate the data of a previous clinical trial, the FDA would likely have the expertise
to evaluate platforms thoroughly and fairly. Initially, proof of principle studies would be performed on
existing drugs or known conditions, such as ERBB2 overexpression in some breast tumors.
(2) Ongoing controls
Once a technique is shown reliable and approved, data may be submitted, initially as part of a VGDS, and
eventually with all INDs or NDAs. Eventual mandatory submission is desirable to increase the total pool of
publicly available data for the synergistic beneﬁts described above. Each submission should include proper
controls to both demonstrate proper experimental design and to verify the eﬃcacy of the technique. To the
extent possible, conditions should be standardized to facilitate comparison. For example, tissue quantities
tested could be correlated to in vivo concentration of a given drug. Control samples should be veriﬁed against
the platform validation data to ensure reproducible results. Obviously, conditions and patient information
must be rigorously detailed to allow sorting of data according to a number of ﬁelds (e.g., patient age, patient
weight, renal function, other medications, and any genetic biomarkers assayed.)
CONCLUSION
Pharmacogenomics is not yet mature enough as a technology for FDA to mandate its submission with INDs or
NDAs, with the possible exception of well-characterized metabolic enzymes explored using pharmacogenetic
techniques. Providing companies incentive to submit data to a central database is a central challenge facing
eﬀorts to marshal the technology to maturity and common use. By setting standards for data submission
that are relatively platform or technique independent, the FDA would allow the technology to continue to
23develop, while at the same time facilitating cumulative data mining for greater understanding of underlying
biological processes and adverse events. Until the platform technologies are validated, however, the FDA’s
largely voluntary submission system is advisable to create a dialogue between industry in the FDA whereby
various obstacles such as standardization and suﬃciency of validation of results can be discussed.
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